JPWO2021119489A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021119489A5 JPWO2021119489A5 JP2022535517A JP2022535517A JPWO2021119489A5 JP WO2021119489 A5 JPWO2021119489 A5 JP WO2021119489A5 JP 2022535517 A JP2022535517 A JP 2022535517A JP 2022535517 A JP2022535517 A JP 2022535517A JP WO2021119489 A5 JPWO2021119489 A5 JP WO2021119489A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- receptor
- optionally
- lilrb1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020003175 receptors Proteins 0.000 claims 14
- 102000005962 receptors Human genes 0.000 claims 14
- 229920001184 polypeptide Polymers 0.000 claims 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims 13
- 102000004569 Leukocyte Immunoglobulin-like Receptor B1 Human genes 0.000 claims 10
- 108010017736 Leukocyte Immunoglobulin-like Receptor B1 Proteins 0.000 claims 10
- 210000002865 immune cell Anatomy 0.000 claims 10
- 239000000427 antigen Substances 0.000 claims 7
- 102000036639 antigens Human genes 0.000 claims 7
- 108091007433 antigens Proteins 0.000 claims 7
- 230000003834 intracellular effect Effects 0.000 claims 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 2
- 239000012190 activator Substances 0.000 claims 2
- 150000001413 amino acids Chemical group 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000005931 immune cell recruitment Effects 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 108091008874 T cell receptors Proteins 0.000 claims 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 102000023732 binding proteins Human genes 0.000 claims 1
- 108091008324 binding proteins Proteins 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 108091008042 inhibitory receptors Proteins 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
Claims (20)
ｉ．）ＮＬＹＡＡＶ（配列番号８）およびＶＴＹＡＥＶ（配列番号９）の両方のＩＴＩＭを含む；
ｉｉ．）ＶＴＹＡＥＶ（配列番号９）およびＶＴＹＡＱＬ（配列番号１０）の両方のＩＴＩＭを含む；
ｉｉｉ．）ＶＴＹＡＱＬ（配列番号１０）およびＳＩＹＡＴＬ（配列番号１１）の両方のＩＴＩＭを含む；
ｉｖ．）ＮＬＹＡＡＶ（配列番号８）、ＶＴＹＡＥＶ（配列番号９）、およびＶＴＹＡＱＬ（配列番号１０）のＩＴＩＭを含む；
ｖ．）ＶＴＹＡＥＶ（配列番号９）、ＶＴＹＡＱＬ（配列番号１０）、およびＳＩＹＡＴＬ（配列番号１１）のＩＴＩＭを含む；または
ｖｉ．）ＮＬＹＡＡＶ（配列番号８）、ＶＴＹＡＥＶ（配列番号９）、ＶＴＹＡＱＬ（配列番号１０）、およびＳＩＹＡＴＬ（配列番号１１）のＩＴＩＭを含む、請求項１または２に記載の受容体。 The intracellular domain is
i. ) containing both NLYAAV (SEQ ID NO: 8) and VTYAEV (SEQ ID NO: 9) ITIMs ;
ii. ) containing both VTYAEV (SEQ ID NO: 9) and VTYAQL (SEQ ID NO: 10) ITIMs;
iii. ) containing both VTYAQL (SEQ ID NO: 10) and SIYATL (SEQ ID NO: 11) ITIMs;
iv. ) containing the ITIMs of NLYAAV (SEQ ID NO: 8), VTYAEV (SEQ ID NO: 9), and VTYAQL (SEQ ID NO: 10);
v. ) comprising the ITIMs of VTYAEV (SEQ ID NO: 9), VTYAQL (SEQ ID NO: 10), and SIYATL (SEQ ID NO: 11); or
vi. 3. The receptor of claim 1 or 2 , comprising the ITIMs of ) NLYAAV (SEQ ID NO: 8), VTYAEV (SEQ ID NO: 9), VTYAQL (SEQ ID NO: 10), and SIYATL (SEQ ID NO: 11) .
前記ＬＩＬＲＢ１ヒンジドメインが、配列番号４、配列番号１８、配列番号１９、配列番号８０、配列番号８１、配列番号８２、配列番号８３、配列番号８４もしくは配列番号９３と同一である配列を含む、または
前記ＬＩＬＲＢ１ヒンジドメインが、配列番号４、配列番号１８、配列番号１９、配列番号８０、配列番号８１、配列番号８２、配列番号８３もしくは配列番号８４と少なくとも９５％同一である配列を含む、または
前記ＬＩＬＲＢ１ヒンジドメインが、配列番号４、配列番号１８、配列番号１９、配列番号８０、配列番号８１、配列番号８２、配列番号８３もしくは配列番号８４と同一である配列を含む、請求項１～７のいずれか一項に記載の受容体。 The LILRB1 hinge domain has a sequence that is at least 95% identical to SEQ ID NO: 4, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 80, SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 84 or SEQ ID NO: 93. contains or
the LILRB1 hinge domain comprises a sequence identical to SEQ ID NO: 4, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 80, SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 84 or SEQ ID NO: 93, or
the LILRB1 hinge domain comprises a sequence that is at least 95% identical to SEQ ID NO: 4, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 80, SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 83 or SEQ ID NO: 84, or
Claims 1-7, wherein the LILRB1 hinge domain comprises a sequence identical to SEQ ID NO: 4, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 80, SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 83 or SEQ ID NO: 84 . The receptor according to any one of .
前記ポリペプチドが、配列番号２０と少なくとも９９％同一である配列を含む、または
前記ポリペプチドが、配列番号２１と少なくとも９９％同一である配列を含む、または
前記ポリペプチドが、配列番号２もしくは配列番号３と少なくとも９９％同一である配列を含む、または
前記ポリペプチドが、配列番号２０と同一である配列を含む、または
前記ポリペプチドが、配列番号２１と同一である配列を含む、または
前記ポリペプチドが、配列番号２もしくは配列番号３と同一である配列を含む、または
前記ポリペプチドが、抗原結合性ドメインを含み、任意には前記抗原結合性ドメインが、前記ＬＩＬＲＢ１細胞外リガンド結合タンパク質以外の抗原結合性ドメインであるか、または、
任意には前記ポリペプチドが２つ以上の抗原結合性ドメインを含む、または
任意には前記抗原結合性ドメインが一本鎖可変断片（ｓｃＦｖ）を含み、任意には前記ｓｃＦｖが配列番号２２～３３のいずれか１つの相補性決定領域（ＣＤＲ）を含むか、または任意には前記ｓｃＦｖが、配列番号３５～４６もしくは１２５のいずれか１つと少なくとも９５％同一である配列を含むか、または任意には前記ｓｃＦｖが配列番号３５～４６もしくは１２５のいずれか１つと同一である配列を含む、または
任意には抗体の重鎖が、配列番号２５～２７もしくは３１～３３のいずれか１つの重鎖ＣＤＲを含み、抗体の軽鎖が、配列番号２２～２４もしくは２８～３０のいずれか１つの軽鎖ＣＤＲを含む、または
任意には抗体の重鎖が、配列番号３５～４６もしくは１２５のいずれか１つの重鎖部分と少なくとも９５％同一である配列を含み、抗体の軽鎖が、配列番号３５～４６もしくは１２５のいずれか１つの軽鎖部分と少なくとも９５％同一である配列を含む、または
任意には抗体の重鎖が、配列番号３５～４６もしくは１２５のいずれか１つの重鎖部分と同一である配列を含み、抗体の軽鎖が、配列番号３５～４６もしくは１２５のいずれか１つの軽鎖部分と同一である配列を含む、請求項１に記載の受容体。 the polypeptide comprises a sequence that is at least 95% identical to SEQ ID NO: 2 or SEQ ID NO: 3, or
the polypeptide comprises a sequence that is at least 99% identical to SEQ ID NO: 20, or
the polypeptide comprises a sequence that is at least 99% identical to SEQ ID NO: 21, or
the polypeptide comprises a sequence that is at least 99% identical to SEQ ID NO: 2 or SEQ ID NO: 3, or
the polypeptide comprises a sequence identical to SEQ ID NO: 20, or
the polypeptide comprises a sequence identical to SEQ ID NO: 21, or
the polypeptide comprises a sequence identical to SEQ ID NO: 2 or SEQ ID NO: 3, or
the polypeptide comprises an antigen binding domain, optionally the antigen binding domain is an antigen binding domain other than the LILRB1 extracellular ligand binding protein, or
Optionally said polypeptide comprises two or more antigen binding domains, or
Optionally said antigen binding domain comprises a single chain variable fragment (scFv), optionally said scFv comprises a complementarity determining region (CDR) of any one of SEQ ID NOs: 22-33; wherein said scFv comprises a sequence that is at least 95% identical to any one of SEQ ID NO: 35-46 or 125, or optionally said scFv is identical to any one of SEQ ID NO: 35-46 or 125. contains an array, or
Optionally, the heavy chain of the antibody comprises a heavy chain CDR of any one of SEQ ID NOs: 25-27 or 31-33, and the light chain of the antibody comprises a light chain CDR of any one of SEQ ID NOs: 22-24 or 28-30. chain CDRs, or
Optionally, the heavy chain of the antibody comprises a sequence that is at least 95% identical to the heavy chain portion of any one of SEQ ID NOs: 35-46 or 125, and the light chain of the antibody comprises a sequence that is at least 95% identical to a heavy chain portion of any one of SEQ ID NOs: 35-46 or 125. comprises a sequence that is at least 95% identical to one light chain portion, or
Optionally, the heavy chain of the antibody comprises a sequence that is identical to the heavy chain portion of any one of SEQ ID NOs: 35-46 or 125, and the light chain of the antibody comprises a sequence that is identical to the heavy chain portion of any one of SEQ ID NOs: 35-46 or 125. 2. A receptor according to claim 1, comprising a sequence that is identical to the light chain portion .
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962946888P | 2019-12-11 | 2019-12-11 | |
| US62/946,888 | 2019-12-11 | ||
| US202063085969P | 2020-09-30 | 2020-09-30 | |
| US63/085,969 | 2020-09-30 | ||
| PCT/US2020/064607 WO2021119489A1 (en) | 2019-12-11 | 2020-12-11 | Lilrb1-based chimeric antigen receptor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023506184A JP2023506184A (en) | 2023-02-15 |
| JPWO2021119489A5 true JPWO2021119489A5 (en) | 2023-12-15 |
Family
ID=74494998
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022535517A Pending JP2023506184A (en) | 2019-12-11 | 2020-12-11 | LILRB1-based chimeric antigen receptor |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US20230029341A1 (en) |
| EP (1) | EP4073103A1 (en) |
| JP (1) | JP2023506184A (en) |
| KR (1) | KR20220124173A (en) |
| CN (1) | CN115052887A (en) |
| AU (2) | AU2020401315B2 (en) |
| BR (1) | BR112022011399A2 (en) |
| CA (1) | CA3161112A1 (en) |
| IL (1) | IL293716A (en) |
| MX (1) | MX2022006962A (en) |
| WO (1) | WO2021119489A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230330227A1 (en) | 2020-08-13 | 2023-10-19 | A2 Biotherapeutics, Inc. | Gene fusions for control of genetically modified cells |
| CA3189510A1 (en) | 2020-08-20 | 2022-02-24 | Julyun OH | Compositions and methods for treating egfr positive cancers |
| AU2021329375A1 (en) | 2020-08-20 | 2023-04-20 | A2 Biotherapeutics, Inc. | Compositions and methods for treating ceacam positive cancers |
| AU2021329371A1 (en) | 2020-08-20 | 2023-04-20 | A2 Biotherapeutics, Inc. | Compositions and methods for treating mesothelin positive cancers |
| WO2022061272A1 (en) * | 2020-09-21 | 2022-03-24 | A2 Biotherapeutics, Inc. | Engineered immune cells |
| MX2023009581A (en) | 2021-02-16 | 2023-08-23 | A2 Biotherapeutics Inc | Compositions and methods for treating her2 positive cancers. |
| WO2023076912A2 (en) * | 2021-10-26 | 2023-05-04 | ImmPACT Bio USA Inc. | Cd4+ and/or cd8+ cell populations comprising icars for use in treatment therapies |
| WO2023172991A2 (en) * | 2022-03-09 | 2023-09-14 | Immpact Bio Usa, Inc. | Bicistronic inhibitory chimeric antigen receptor (icar)/activating chimeric antigen receptor (acar) constructs for use in cancer therapies |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| CA2386270A1 (en) | 1999-10-15 | 2001-04-26 | University Of Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| MXPA02008265A (en) | 2000-02-24 | 2004-09-10 | Xcyte Therapies Inc | Simultaneous stimulation and concentration of cells. |
| WO2001096584A2 (en) | 2000-06-12 | 2001-12-20 | Akkadix Corporation | Materials and methods for the control of nematodes |
| US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
| US7446190B2 (en) * | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| EP3363907A1 (en) | 2004-05-27 | 2018-08-22 | The Trustees of the University of Pennsylvania | Novel artificial antigen presenting cells and uses therefor |
| WO2013126712A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer |
| EP3623380A1 (en) | 2013-03-15 | 2020-03-18 | Michael C. Milone | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| NZ712693A (en) | 2013-03-15 | 2021-07-30 | Memorial Sloan Kettering Cancer Center | Compositions and methods for immunotherapy |
| WO2015017214A1 (en) | 2013-07-29 | 2015-02-05 | Bluebird Bio, Inc. | Multipartite signaling proteins and uses thereof |
| KR101962524B1 (en) * | 2013-11-21 | 2019-07-17 | 유씨엘 비즈니스 피엘씨 | Cell |
| EP3102609A4 (en) | 2014-02-04 | 2017-08-23 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Methods for producing autologous t cells useful to treat b cell malignancies and other cancers and compositions thereof |
| EP3209769B1 (en) * | 2014-10-24 | 2020-08-05 | The Board of Trustees of the Leland Stanford Junior University | Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance |
| CA2967222C (en) | 2014-11-12 | 2023-10-31 | Rinat Neuroscience Corp. | Inhibitory chimeric antigen receptors |
| WO2016097231A2 (en) | 2014-12-17 | 2016-06-23 | Cellectis | INHIBITORY CHIMERIC ANTIGEN RECEPTOR (iCAR OR N-CAR) EXPRESSING NON-T CELL TRANSDUCTION DOMAIN |
| WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| CN108064283B (en) | 2015-02-24 | 2024-01-09 | 加利福尼亚大学董事会 | Binding triggered transcription switches and methods of use thereof |
| CN107533051B (en) | 2015-03-27 | 2020-11-13 | 南加利福尼亚大学 | HLA-G as a novel target for CAR T cell immunotherapy |
| GB201509413D0 (en) * | 2015-06-01 | 2015-07-15 | Ucl Business Plc | Fusion protein |
| MA42895A (en) | 2015-07-15 | 2018-05-23 | Juno Therapeutics Inc | MODIFIED CELLS FOR ADOPTIVE CELL THERAPY |
| US20210206826A1 (en) | 2015-11-19 | 2021-07-08 | The Regents Of The University Of California | Conditionally repressible immune cell receptors and methods of use thereof |
| US11530252B2 (en) | 2015-11-23 | 2022-12-20 | Trustees Of Boston University | Methods and compositions relating to chimeric antigen receptors |
| US20190255186A1 (en) | 2015-12-02 | 2019-08-22 | Innovative Targeting Solutions Inc. | Single variable domain t-cell receptors |
| BR112018068354A2 (en) | 2016-03-11 | 2019-01-15 | Bluebird Bio Inc | immune effector cells of the edited genome |
| BR112019006006A2 (en) | 2016-09-28 | 2019-06-25 | Gavish Galilee Bio Appl Ltd | nucleic acid molecule, vector, methods for preparing a chimeric inhibitory antigen receptor, preparing a safe effector immune cell, selecting a custom biomarker, and treating cancer in a patient with a tumor, safe effector immune cell, and, combination of two or more nucleic acid molecules. |
| US20190375815A1 (en) | 2017-01-31 | 2019-12-12 | Novartis Ag | Treatment of cancer using chimeric t cell receptor proteins having multiple specificities |
| EP3579877A4 (en) | 2017-02-09 | 2020-12-09 | The Regents of The University of California | Chimeric t cell antigen receptors and methods of use thereof |
| CN110621694A (en) * | 2017-05-15 | 2019-12-27 | 奥托路斯有限公司 | Cells comprising Chimeric Antigen Receptors (CAR) |
| GB201707783D0 (en) | 2017-05-15 | 2017-06-28 | Autolus Ltd | Cell |
| GB201707779D0 (en) | 2017-05-15 | 2017-06-28 | Autolus Ltd | Cell |
| JP7281774B2 (en) | 2017-09-19 | 2023-05-26 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | ANTI-HLA-A2 ANTIBODY AND METHOD OF USE THEREOF |
| HUE061502T2 (en) | 2017-09-28 | 2023-07-28 | Immpact Bio Ltd | A universal platform for preparing an inhibitory chimeric antigen receptor (icar) |
| EP3707166A4 (en) | 2017-11-06 | 2021-11-24 | Daniel J. Monticello | Dominant negative ligand chimeric antigen receptor systems |
| WO2019241549A1 (en) | 2018-06-15 | 2019-12-19 | A2 Biotherapeutics, Inc. | Foxp3-expressing car-t regulatory cells |
| WO2020065406A2 (en) | 2018-09-28 | 2020-04-02 | Immpact-Bio Ltd. | Methods for identifying activating antigen receptor (acar)/inhibitory chimeric antigen receptor (icar) pairs for use in cancer therapies |
| CN113164576A (en) | 2018-10-05 | 2021-07-23 | 圣安娜儿童癌症研究中心 | Chimeric Antigen Receptor (CAR) groups |
| EP3632461A1 (en) | 2018-10-05 | 2020-04-08 | St. Anna Kinderkrebsforschung | A group of chimeric antigen receptors (cars) |
| WO2021030153A2 (en) | 2019-08-09 | 2021-02-18 | A2 Biotherapeutics, Inc. | Engineered t cell receptors and uses thereof |
| WO2021030182A1 (en) | 2019-08-09 | 2021-02-18 | A2 Biotherapeutics, Inc. | Bifunctional single variable domain t cell receptors and uses thereof |
| BR112022002465A2 (en) | 2019-08-09 | 2022-05-03 | A2 Biotherapeutics Inc | Cell surface receptors responsive to loss of heterozygosity |
| EP4058561A1 (en) | 2019-11-12 | 2022-09-21 | A2 Biotherapeutics, Inc. | Engineered t cell receptors and uses thereof |
-
2020
- 2020-12-11 EP EP20848889.0A patent/EP4073103A1/en active Pending
- 2020-12-11 CA CA3161112A patent/CA3161112A1/en active Pending
- 2020-12-11 IL IL293716A patent/IL293716A/en unknown
- 2020-12-11 AU AU2020401315A patent/AU2020401315B2/en active Active
- 2020-12-11 US US17/757,056 patent/US20230029341A1/en active Pending
- 2020-12-11 WO PCT/US2020/064607 patent/WO2021119489A1/en unknown
- 2020-12-11 CN CN202080095978.4A patent/CN115052887A/en active Pending
- 2020-12-11 JP JP2022535517A patent/JP2023506184A/en active Pending
- 2020-12-11 BR BR112022011399A patent/BR112022011399A2/en unknown
- 2020-12-11 MX MX2022006962A patent/MX2022006962A/en unknown
- 2020-12-11 KR KR1020227022970A patent/KR20220124173A/en unknown
-
2021
- 2021-04-14 US US17/230,637 patent/US11254726B2/en active Active
-
2022
- 2022-01-31 US US17/589,088 patent/US20220162287A1/en active Pending
- 2022-01-31 US US17/589,093 patent/US20220153807A1/en active Pending
- 2022-05-12 US US17/663,148 patent/US20220289818A1/en active Pending
-
2024
- 2024-02-06 AU AU2024200719A patent/AU2024200719A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101455447B1 (en) | MUC1* Antibodies | |
| JP2016138129A5 (en) | ||
| JP7475054B2 (en) | Bispecific antibody compositions and methods of use thereof | |
| JP2018518540A5 (en) | ||
| US11639388B2 (en) | CD3 antigen binding fragment and application thereof | |
| CN107750255A (en) | Bispecific antibody constructs for CDH3 and CD3 | |
| CN113573728A (en) | Therapeutic SIRP alpha antibodies | |
| BR112019017629A2 (en) | antigen-binding receptor, isolated polynucleotide, vector, transduced t cell, methods for treating a disease and for inducing lysis, use of the receptor and receptor | |
| JP7036729B2 (en) | Therapeutic anti-CD9 antibody | |
| CA2794407A1 (en) | Humanized anti cxcr4 antibodies for the treatment of cancer | |
| TWI821474B (en) | Cd3 antibody and its pharmaceutical use thereof | |
| WO2020114479A1 (en) | Multispecific protein molecule | |
| WO2022161425A1 (en) | Humanized antibody against tnfr2 and use thereof | |
| WO2017121758A1 (en) | Combination therapy comprising a superagonistic antibody against interleukin-2 and a checkpoint blockade agent | |
| CN111995682A (en) | Anti-human SIRP alpha monoclonal antibody and application thereof | |
| JP5818003B2 (en) | High-functional variant of humanized anti-EGFR antibody variable region | |
| WO2022007543A1 (en) | Anti-fgl1 antibody and use thereof | |
| CN116744948A (en) | Cells comprising T cell antigen conjugates and uses thereof | |
| JP2022512672A (en) | Binding protein-toxin fusion containing anthracyclines, and its use in immuno-oncological applications | |
| DK2726507T3 (en) | ANTIBODY AGAINST THE PROSTATE-SPECIFIC STEM CELL ANTIGEN AND ITS USE | |
| JP2016529213A5 (en) | ||
| JPWO2021119489A5 (en) | ||
| JP2023524238A (en) | Therapeutic SIRPα antibodies | |
| CN115361955A (en) | Chimeric antigen receptor T cell compositions against BCMA and methods and uses thereof | |
| WO2019241127A1 (en) | Materials and methods for treating stress-related disorders and cancer |